Navigation Links
New Board Director Appointed
Date:3/15/2010

DUBLIN, March 15, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces the appointment of Bill Burns to its Board as a Non Executive Director with immediate effect. Mr Burns has also been appointed a member of Shire's Remuneration Committee.

Mr Burns has a long and distinguished career in the global pharmaceuticals industry, having worked for many years for Roche; most recently as CEO of their Pharmaceuticals Division and as a member of the Roche Group Corporate Executive Committee. He has extensive experience of international pharmaceuticals and of mergers and acquisitions. Among his many achievements during his time with Roche, he had significant involvement in the acquisition and privatisation of Genentech, he led the integration of Boehringer Mannheim Therapeutics and he played a lead role in the negotiations resulting in Roche becoming a majority owner of Chugai in Japan.

Mr Burns retired from Roche in January this year. He was appointed on 2 March 2010 to be a member of the Board of Directors of Roche Holdings Ltd. Mr Burns is also on the Board of Directors of Chugai Pharmaceuticals and of Genentech Inc.

Says Matthew Emmens, Shire Chairman:

"Bill Burns' global pharmaceutical experience will be invaluable to Shire. Shire is growing its business through extending its global reach with established operations now in 28 countries and a range of exciting growth-driving products with rights around the world."

Says Bill Burns:

"I'm attracted by the approach Shire takes to address specific medical needs, and the Company's track record of success and I look forward to making a contribution to this ambitious and exciting player in the global pharmaceutical industry."

There is no further information that is required to be disclosed under 9.6.13R of the United Kingdom listing rules.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

SOURCE Shire plc

Back to top
'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral appoints two new board members
2. Bone Biologics Announces Another Round of Equity and Debt Investment by Musculoskeletal Transplant Foundation and the Addition of Board Member, Mark Spilker
3. 3SBio Announces Changes to its Board of Directors
4. Axial Exchange Recruits Karen Evans, Former Fed CIO, to Advisory Board
5. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
6. Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor
7. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
8. Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
9. The Advisory Board Company to Present at Upcoming Conferences
10. MODA Names New Members to QC Micro Advisory Board
11. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... research organization (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) assay for ... a 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay meets additional needs ...
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg based clinical ... Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads to a ... in a group of 20 patients carrying 11778, 14484 and 3460 mutations and having ...
(Date:4/27/2017)... ... April 27, 2017 , ... Sierra Instruments ... based on capillary thermal mass flow technology provide exponentially more accurate mass flow ... Over 80% of all industrial processes—such as those involving chemical reactions, combustion, respiration, ...
(Date:4/27/2017)...  Pendant Biosciences, Inc. (formerly Nanoferix, Inc.), a privately-held ... delivery technologies, today announced that it has been accepted ... Toronto . Shawn Glinter , ... "We are excited to become part of the JLABS ... honored to be the first Tennessee ...
Breaking Biology Technology:
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
(Date:3/7/2017)... 7, 2017   HireVue , the leading provider ... identify the best talent, faster, today announced the additions ... (CSO) and Diana Kucer as Chief Marketing ... executive team poised to drive continued growth in the ... year of record bookings in 2017. "Companies ...
Breaking Biology News(10 mins):